A drug called daraxonrasib has achieved what oncologists have been pursuing for decades – meaningful survival benefit in metastatic pancreatic cancer by successfully targeting the KRAS gene mutation that drives more than 90 percent of cases. Revolution Medicines presented results from the Phase 3 RASolute 302 clinical trial on May 31, 2026, showing that patients treated with daraxonrasib lived a median of 13.2 months compared to 6.7 months for patients receiving standard chemotherapy – nearly doubling overall survival and reducing the risk of death by 60 percent. The results were published simultaneously in the New England Journal of Medicine, the most prestigious medical journal in the world, and have been described by leading cancer specialists as a landmark moment for a disease that has resisted effective treatment for longer than virtually any other major cancer type.

Pancreatic cancer has carried one of the worst prognoses of any common cancer for half a century. The five-year survival rate for pancreatic cancer overall remains below 15 percent, and for metastatic pancreatic cancer – cancer that has spread beyond the pancreas to other organs, which describes most cases at diagnosis because the disease typically produces no symptoms until it is advanced – the prognosis is far grimmer. The standard of care for metastatic pancreatic cancer has been chemotherapy combinations that extend survival by months rather than years, making the daraxonrasib result the most significant clinical advance in this disease in a generation.

Why KRAS Was Called Undruggable – and How Daraxonrasib Changed That

The KRAS gene encodes a protein that acts as a molecular switch inside cells, turning on signals that drive cell growth and division. In its mutated form, which occurs in approximately 90 to 95 percent of pancreatic cancer cases and in significant fractions of lung and colon cancers as well, KRAS becomes permanently locked in the “on” position, continuously signaling cells to grow and divide uncontrollably. For decades, drug developers attempted and failed to find molecules that could attach to the mutated KRAS protein and block its activity, eventually concluding that the protein’s structure offered no suitable binding site for a conventional small molecule drug – earning KRAS the label “undruggable.”

Daraxonrasib circumvents this problem through an indirect mechanism. Rather than binding to KRAS directly, the drug attaches to a separate molecule called cyclophilin A, which is involved in protein folding. By binding to cyclophilin A, daraxonrasib creates a molecular complex that can then engage the active KRAS protein and shut down its ability to signal cancer cells to multiply. The approach essentially uses KRAS’s own molecular neighborhood against it rather than trying to directly block the protein that proved inaccessible to direct attack. The result is a drug that can be taken daily by mouth – not intravenously – that reaches and disables a target that resisted every previous pharmacological approach. The advance parallels the kind of computational innovation behind AlphaFold 3’s drug interaction predictions, both representing a shift toward understanding molecular systems rather than targeting single proteins in isolation.

The Phase 3 Trial Results in Detail

The RASolute 302 trial enrolled 500 patients with metastatic pancreatic cancer who had received at least one prior line of treatment – meaning these were patients whose cancer had continued progressing despite standard chemotherapy. Patients were randomized to receive either daraxonrasib or physician’s choice chemotherapy (typically a second-line regimen), with the primary endpoint being overall survival. The trial hit its primary endpoint with statistical significance: median overall survival of 13.2 months with daraxonrasib versus 6.7 months with chemotherapy, a hazard ratio of 0.40, meaning patients on daraxonrasib had 60 percent lower risk of death at any given time point than those on chemotherapy.

The progression-free survival data – measuring how long patients went before their cancer started growing again – also favored daraxonrasib significantly. Objective response rates, meaning the fraction of patients whose tumors shrank measurably in response to treatment, were higher with daraxonrasib than with chemotherapy. Side effect profiles, while present as with any cancer treatment, were described by investigators as manageable and consistent with the drug’s mechanism of action. Importantly, daraxonrasib is an oral daily pill, not an intravenous infusion – a practical advantage for patient quality of life that is not captured in survival statistics but matters substantially to people living with cancer.

Regulatory Path and What Comes Next

Revolution Medicines received a “safe to proceed” letter from the FDA in May 2026, allowing expanded use of daraxonrasib in additional patient populations while the regulatory review process continues. The company has indicated it intends to submit data to the FDA for formal approval review, a process that could result in an approved indication for daraxonrasib in previously treated metastatic pancreatic cancer within the next 12 to 18 months if the agency moves on a standard timeline. A Breakthrough Therapy Designation or Priority Review status could accelerate that timeline if the FDA grants it based on the strength of the RASolute 302 results.

For the approximately 64,000 Americans diagnosed with pancreatic cancer each year – and the roughly 57,000 who die from it annually – a drug that meaningfully extends life for patients with advanced disease represents a genuine change in the clinical landscape rather than an incremental improvement. Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, and UCHealth are among the major cancer centers that have published commentary on the daraxonrasib results describing their potential significance for the field. The result also reinvigorates the broader KRAS targeting research program across the pharmaceutical industry, as the proof that KRAS can be engaged pharmacologically opens conceptual space for additional approaches targeting KRAS and related RAS family proteins in multiple cancer types. The accelerating pace of health research advances in 2026 reflects both increased research investment and new computational tools enabling faster drug discovery and trial design.

Pancreatic Cancer Detection and the Broader Challenge

Even a highly effective treatment for metastatic pancreatic cancer faces the fundamental challenge that most pancreatic cancers are diagnosed at an advanced stage because the disease produces no reliable early symptoms. The pancreas sits deep within the abdomen, making it inaccessible to routine physical examination, and there is no widely deployed screening test for pancreatic cancer equivalent to colonoscopy for colon cancer or mammography for breast cancer. By the time patients experience symptoms – abdominal pain, jaundice, unexplained weight loss – the cancer has typically spread beyond the point where surgical removal is possible.

Improving early detection is the other essential pillar of reducing pancreatic cancer mortality alongside the treatment advances represented by daraxonrasib. Liquid biopsy technologies that detect cancer DNA fragments in blood samples are under active development for pancreatic cancer early detection, with several research programs showing promising sensitivity in identifying early-stage disease. The combination of a transformative treatment for advanced disease and improved early detection would address pancreatic cancer’s lethality from both ends of the clinical timeline. For now, the daraxonrasib results give patients with metastatic disease a reason for cautious optimism that has not existed for decades. The broader progress in medical research in 2026, from wearable health monitoring to breakthrough oncology drugs, reflects a period of accelerating medical innovation across multiple fronts simultaneously.